{"id":"NCT02162771","sponsor":"Celltrion","briefTitle":"To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan","officialTitle":"A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07-14","primaryCompletion":"2016-01-12","completion":"2018-12-29","firstPosted":"2014-06-13","resultsPosted":"2020-01-29","lastUpdate":"2020-01-29"},"enrollment":140,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma, Follicular"],"interventions":[{"type":"BIOLOGICAL","name":"Rituxan","otherNames":["Rituximab"]},{"type":"BIOLOGICAL","name":"CT-P10","otherNames":["Rituximab"]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Vincristine","otherNames":[]},{"type":"DRUG","name":"Prednisone","otherNames":["Prednisolone"]}],"arms":[{"label":"CT-P10","type":"EXPERIMENTAL"},{"label":"Rituxan","type":"ACTIVE_COMPARATOR"}],"summary":"This study is a Phase 3 prospective, randomised, parallel-group, active controlled, double blind, multicentre, international study with 2 coprimary endpoints designed to demonstrate equivalence in pharmacokinetics (Part 1), as well as noninferiority in efficacy (Part 2), of CT-P10 to Rituxan when coadministered with CVP and to assess efficacy and safety in patients with advanced (stage III-IV) FL. Part 1 and Part 2 of the study will run in parallel.","primaryOutcome":{"measure":"Area Under the Serum Concentration-time Curve at Steady State (AUCtau)","timeFrame":"Core Cycle 4 (Week 12)","effectByArm":[{"arm":"CT-P10","deltaMin":41002.43,"sd":1.136},{"arm":"Rituxan","deltaMin":40099.08,"sd":1.143}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28712940","34477816"],"seeAlso":["http://www.celltrion.com"]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":70},"commonTop":["Neutropenia","Infusion related reaction","Upper respiratory tract infection","Neuropathy peripheral","Constipation"]}}